CD70-targeted CAR-T immunotherapy News

|||||||||| Journal, CAR T-Cell Therapy: Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway. (Pubmed Central) - Nov 24, 2021
These data demonstrate the application of CD70 CAR-T cell therapeutic strategies for RCC and the cross-talk between targeting DNA damage responses and antitumor CAR-T cell therapy. These findings provide insight into the mechanisms of PARPis in CAR-T cell therapy for RCC and suggest a promising adjuvant therapeutic strategy for CAR-T cell therapy in solid tumors.

|||||||||| temozolomide / Generic mfg.
Dose intensified temozolomide improves infiltration of CD70 CAR T cells into the GBM tumor microenvironment (Exhibit Hall D) - Nov 16, 2021 - Abstract #SNO2021SNO_284;
DI TMZ preconditioning results in greater CD70 CAR T cell trafficking to the tumor without T cell exhaustion compared to lower doses of TMZ. The affects of TMZ on the immune microenvironment to enhance CAR T cell regimens warrants further study.

|||||||||| CD70-directed CAR-T / Massachusetts General Hospital
Rational Chemical and Genetic Modifications Enhance Avidity and Function of CD70-Directed CAR-T-Cells for Myeloid Leukemia (GWCC - B405-B407, Level 4) - Nov 5, 2021 - Abstract #ASH2021ASH_1779;
Our findings demonstrate that natural-ligand binding domains of CARs targeting CD70 in AML can be effective but require mechanisms to overcome surface cleavage. CD70-targeted CARs comprised of a fusion of truncated CD27 to a CD8 hinge and transmembrane domain have promise in patients with AML, with and without combination with azacitidine.

||||||||||  CD70 CAR T-cells / Shanghai Yake Biotech
Enrollment open:  CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases (clinicaltrials.gov) -  Nov 3, 2021
P1, N=108, Recruiting,  Sponsor: Zhejiang University
CD70-targeted CARs comprised of a fusion of truncated CD27 to a CD8 hinge and transmembrane domain have promise in patients with AML, with and without combination with azacitidine. Not yet recruiting --> Recruiting

|||||||||| CISH gene-knockout anti-CD70-CAR NK cells demonstrate potent anti-tumor activity against solid tumor cell lines and provide partial resistance to tumor microenvironment inhibition (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_267;
Conclusions In summary, we show CISH gene-knockout CD70-CAR NK cells demonstrate potent anti-tumor activity against relevant solid tumor cell lines and partially provide resistance to tumor microenvironment inhibition. These data support the further exploration of CISH gene-knockout CD70 CAR NK cells for clinical application.

|||||||||| Journal, CAR T-Cell Therapy: CD70-targeting CAR-T cells have potential activity against CD19-negative B-cell Lymphoma. (Pubmed Central) - Jul 28, 2021
These data support the further exploration of CISH gene-knockout CD70 CAR NK cells for clinical application. No abstract available

||||||||||  CD70 CAR T-cells / Shanghai Yake Biotech
New P1 trial:  CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases (clinicaltrials.gov) -  Dec 10, 2020
P1, N=108, Not yet recruiting,  Sponsor: Zhejiang University



	Diseases Companies Products Productz Mechanisms of Action Sites